A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 4, 2014, Pages 839-845

  Soares, Heloisa P ^a   Bayraktar, Soley ^a   Blaya, Marcelo ^b   Lopes, Gilberto ^c   Merchan, Jaime ^a   Macintyre, Jessica ^a   Mayo, Carlos ^a   Green, Mark R ^a   Silva, Orlando ^a   Levi, Joe ^a   Walker, Gail ^a   Rocha Lima, Caio M ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b TULANE UNIVERSITY   (United States)

^c Johns Hopkins Singapore   (Singapore)

Author keywords

Capecitabine; Docetaxel; Gemcitabine pretreated; Pancreatic cancer; Second line chemotherapy

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; DOCETAXEL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DRUG EFFICACY; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; STOMATITIS; TIME TO TREATMENT; TOXIC HEPATITIS; TREATMENT FAILURE; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84898059554     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2414-z     Document Type: Article

References (24)

1. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-20132013. Accessed 4 Sept 2013
2. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
3. Von Hoff DD, Ervin T, Arena FP, Gabriela Chiorean E, Infante JR, Moore MJ et al (2013) Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. In: ASCO annual meeting. Chicago, IL. J Clin Oncol 31: abstract 4005
4. Oettle H, Pelzer U, Stieler J et al (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-pretreated advanced pancreatic cancer (CONKO 003). In: ASCO annual meeting proceedings 2005. J Clin Oncol 23: abstract 4031
5. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine pretreated pancreatic cancer. Final results of the CONKO 003 study. In: ASCO annual meeting proceedings. J Clin Oncol 26: abstract 4508
6. Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676-1681
7. Fujimoto-Ouchi K, Tanaka Y, Tominaga T (2001) Schedule dependency of antitumor activity in combination therapy with capecitabine/5-deoxy-5- fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7:1079-1086
8. Maher JF, Villalona-Calero MA (2002) Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2:287-293
9. O'Shaughnessy JA, Blum JL (2006) Capecitabine/taxane combination therapy: evolving clinical utility in breast cancer. Clin Breast Cancer 7:42-50
10. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
11. Androulakis N, Kourousis C, Dimopoulos MA et al (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17:1779-1785
12. Rougier P, Adenis A, Ducreux M et al (2000) A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36:1016-1025
13. Boeck S, Wilkowski R, Bruns CJ et al (2007) Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73:221-227
14. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-pretreated advanced pancreatic cancer. J Clin Oncol 25:4787-4792
15. Xiong HQ, Varadhachary GR, Blais JC et al (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046-2052
16. van Meerten ELP, Gelderblom H, Bloem JL (2010) RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 20:1456-1467
17. Saif MW, Syrigos K, Penney R, Kaley K (2010) Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 30:2905-2909
18. Katopodis O, Polyzos A, Kentepozidis N et al (2011) Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 67:361-368
19. Chua YJ, Cunningham D (2006) Chemotherapy for advanced pancreatic cancer. Best Pract Res Clin Gastroenterol 20:327-348
20. Fine R, Moorer G, Sherman W, Chu, Maurer KM, Chabot J et al (2009) Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. Clin Oncol 27(15 Suppl): abstract 4623
21. Ulrich-Pur H, Raderer M, Verena Kornek G et al (2003) Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88:1180-1184
22. Jacobs AD, Burris HA, Rivkin S et al (2004) A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol 22(Suppl):Abstr 4013
23. Astsaturov IA, Meropol NJ, Alpaugh RK et al (2007) A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. J Clin Oncol 25(18S):Abstr 4556
24. Hwang JY, Yoo C, Kim T et al (2009) A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol 27(15S):Abstr 4618